<DOC>
	<DOCNO>NCT02367690</DOCNO>
	<brief_summary>Patients eligible diabetic foot ulcer screen , treat , follow complete ulcer closure . This randomized trial . All patient receive standard-of-care treatment . Additionally , patient receive treatment topical Selinexor gel receive topical placebo gel .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics Topical Selinexor ( KPT-330 ) Diabetic Foot Ulcer ( DFU ) Patients</brief_title>
	<detailed_description>Approximately 30 patient meet eligibility criterion enrol . Eligible patient diabetic foot ulcer screen , randomize , treat , follow complete ulcer closure . After screen , qualified patient treat 12 week . Patients achieve complete ulcer closure follow additional 12 week . All patient receive standard-of-care treatment . After randomization patient treat topical Selinexor gel twice weekly patient treat topical placebo gel twice weekly . Patients receive Selinexor assign sequential treatment cohort , either 10 μM ( μmol/L ) , 30 μM , 70 μM dose .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Patient clinical diagnosis Type I Type II diabetes mellitus HbA1c ≤ 10.0 BMI ≤40 . The DFU ( ) treat must : Anatomically discrete , Nonhealing , persist ≤12 month Measures 1 cm2 ≤ area ≤ 5 cm2 follow debridement , Has Wagner Grade 1 ( i.e. , involve bone , muscle , tendon , ligament ) , The Target DFU locate distal ankle ( i.e. , malleolus ) , Is able adequately offload . The patient adequate arterial blood supply affect limb screening . Patient inability perceive 10 gram pressure periulcer area region affect foot toe use SemmesWeinstein 5.07 monofilament screening . Patient foot ulcer clearly nondiabetic pathophysiology . Patient two ( 2 ) DFUs target low extremity . DFU clinically infect . Patient active osteomyelitis foot active , uncontrolled , connective tissue disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Foot Ulcers</keyword>
	<keyword>DFU</keyword>
	<keyword>KPT-330</keyword>
	<keyword>Selinexor</keyword>
	<keyword>Karyopharm</keyword>
</DOC>